Candriam SCA’s Jazz Pharmaceuticals JAZZ Stock Holding History

Candriam SCA’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$1K	–	817
2020 Q2	$1K	Buy	+10	New	+$1.11K	﹤0.01%	796

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Candriam SCA's JAZZ Position: Q3 2020 in Review

Candriam SCA sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 10 shares — an estimated $1K sold.

Candriam SCA first reported a position in JAZZ in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Candriam SCA reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Candriam SCA sold 10 Jazz Pharmaceuticals shares in Q3 2020, an estimated $1K.
Candriam SCA first reported a position in Jazz Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Candriam SCA's Jazz Pharmaceuticals position peaked at $1K in Q2 2020.
389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.